PMID- 24333676
OWN - NLM
STAT- MEDLINE
DCOM- 20141203
LR  - 20191231
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Linking)
VI  - 79
DP  - 2014 Apr
TI  - DOR(2)-selective but not DOR(1)-selective antagonist abolishes anxiolytic-like 
      effects of the delta opioid receptor agonist KNT-127.
PG  - 314-20
LID - S0028-3908(13)00567-4 [pii]
LID - 10.1016/j.neuropharm.2013.11.021 [doi]
AB  - Recently, we reported that the delta opioid receptor (DOR) agonist KNT-127 produces 
      anxiolytic-like effects in behaving rats. Here, we report on the roles of DOR 
      subtypes ( DOR(1) and DOR(2)) play in mediating KNT-127-induced anxiolytic-like 
      effects. Pretreatment with the DOR(2)-selective antagonist naltriben (NTB; 
      0.05mg/kg, s.c.) completely abolished KNT-127 (3.0mg/kg, s.c.)-induced 
      anxiolytic-like effects in rats performing the elevated plus-maze task. By 
      contrast, the DOR(1)-selective antagonist 7-benzylidenenaltrexone (BNTX; 
      0.5mg/kg, s.c.) produced no effect at a dose that completely blocked the 
      antinociceptive effects of KNT-127. These findings were also supported by results 
      from a light/dark test and open-field test. We clearly demonstrated that the 
      DOR(2)-selective antagonist, but not the DOR(1)-selective antagonist, abolishes 
      the anxiolytic-like effects of the DOR agonist KNT-127, suggesting different 
      roles of these DOR subtypes in anxiety. We propose that DOR(2)-selective agonists 
      would be good candidates for future development of anxiolytic drugs.
CI  - Crown Copyright (c) 2013. Published by Elsevier Ltd. All rights reserved.
FAU - Sugiyama, Azusa
AU  - Sugiyama A
AD  - Department of Neuropsychopharmacology, National Institute of Mental Health, 
      National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashimachi, Kodaira, 
      Tokyo 187-8553, Japan; Laboratory of Pharmacology, Faculty of Pharmaceutical 
      Sciences, Tokyo University of Science, Chiba 278-8510, Japan.
FAU - Nagase, Hiroshi
AU  - Nagase H
AD  - International Institute for Integrative Sleep Medicine, University of Tsukuba, 
      Ibaraki 305-8577, Japan.
FAU - Oka, Jun-Ichiro
AU  - Oka J
AD  - Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University 
      of Science, Chiba 278-8510, Japan.
FAU - Yamada, Mitsuhiko
AU  - Yamada M
AD  - Department of Neuropsychopharmacology, National Institute of Mental Health, 
      National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashimachi, Kodaira, 
      Tokyo 187-8553, Japan.
FAU - Saitoh, Akiyoshi
AU  - Saitoh A
AD  - Department of Neuropsychopharmacology, National Institute of Mental Health, 
      National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashimachi, Kodaira, 
      Tokyo 187-8553, Japan. Electronic address: asaito@ncnp.go.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131212
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Anti-Anxiety Agents)
RN  - 0 (Benzylidene Compounds)
RN  - 0 (DOR2 protein, rat)
RN  - 0 (KNT 127)
RN  - 0 (Morphinans)
RN  - 0 (Narcotic Antagonists)
RN  - 0 (Oprd1 protein, rat)
RN  - 0 (Receptors, Opioid, delta)
RN  - 111555-58-9 (naltrindole benzofuran)
RN  - 129468-28-6 (7-benzylidenenaltrexone)
RN  - 1HG84L3525 (Formaldehyde)
RN  - 5S6W795CQM (Naltrexone)
SB  - IM
MH  - Animals
MH  - Anti-Anxiety Agents/*pharmacology
MH  - Anxiety/drug therapy
MH  - Benzylidene Compounds/pharmacology
MH  - Exploratory Behavior/drug effects
MH  - Formaldehyde
MH  - Male
MH  - Maze Learning/drug effects
MH  - Morphinans/*pharmacology
MH  - Naltrexone/analogs & derivatives/pharmacology
MH  - Narcotic Antagonists/*pharmacology
MH  - Neuropsychological Tests
MH  - Nociception/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Opioid, delta/*antagonists & inhibitors
OTO - NOTNLM
OT  - Analgesia
OT  - Animal models
OT  - Antidepressants
OT  - Anxiolytics
OT  - Inflammatory pain
EDAT- 2013/12/18 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/12/17 06:00
PHST- 2013/09/10 00:00 [received]
PHST- 2013/11/06 00:00 [revised]
PHST- 2013/11/23 00:00 [accepted]
PHST- 2013/12/17 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - S0028-3908(13)00567-4 [pii]
AID - 10.1016/j.neuropharm.2013.11.021 [doi]
PST - ppublish
SO  - Neuropharmacology. 2014 Apr;79:314-20. doi: 10.1016/j.neuropharm.2013.11.021. 
      Epub 2013 Dec 12.